Abstract

In vitro studies suggest an association between raised levels of tissue factor and restenosis after coronary percutaneous transluminal angioplasty (PTA). This prospective, controlled study examined the association between plasma tissue factor concentrations and restenosis after femoropopliteal PTA. Plasma samples from ten healthy controls and 36 patients with unilateral claudication undergoing femoropopliteal PTA were collected at baseline and, in the patients with claudication, at 24 h and 1, 3 and 6 months after PTA. Clinical assessment and arterial duplex imaging were performed before and at the same time points after PTA to identify restenosis. Plasma tissue factor was measured using a specific enzyme-linked immunosorbent assay. Baseline plasma tissue factor concentrations were significantly higher in patients with claudication (median 3.4 (interquartile range (i.q.r.) 1.3-7.4) ng/ml) than in controls (median 1.2 (i.q.r. 0.5-1.8) ng/ml) (P < 0.050). Baseline tissue factor concentrations were significantly higher in the ten patients with claudication who developed restenosis after PTA (median 7.0 (i.q.r. 3.4-183.5) ng/ml) than in those who did not (median 1.7 (i.q.r. 1.3-7.2) ng/ml) (P < 0.050). In addition, plasma tissue factor levels increased significantly over time in the patients who developed restenosis after PTA. High baseline and progressive increases in the plasma tissue factor concentration were useful predictors of restenosis after femoropopliteal angioplasty.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.